As 2019 rolls in, we expect to see a flurry of approvals in the Japanese regenerative medicine arena, with regulatory decisions anticipated by the end of the year for Novartis Pharma’s CAR-T therapy and many more products, which could bring…
HOME > COMMENTARY
COMMENTARY
- As AG Momentum Continues, Mucosta AG to Hit Shelves 8 Years after Gx Entry
June 14, 2017
- MHLW, MOF Agreed on CEFP Working Group Report, Continuation of Premium As-Is Seems Difficult
May 11, 2017
- Will Government Take the Lead in Pricing Debate towards 2017 Fiscal Blueprint?
April 19, 2017
- “Cash-and-Carry Dealers” and Their Peculiar Business Practices in the Spotlight in Wake of Counterfeit Harvoni Scandal
April 12, 2017
- Is the Government’s 70% Interim Generic Share Target Achievable?
March 13, 2017
- Growing Hopes for Control of Hepatic Cancer; Road to Cures for Hepatitis B, NASH Might Be in Sight
March 7, 2017
- Will NHI Pricing Reform in Sluggish Domestic Market Trigger Industry Reorganization?
February 6, 2017
- Top-Notch Talents Needed for Pharma’s Lobbying Activities; Stay Current with Policymaking Moves
January 30, 2017
- Hepatology Society Revises Hep C Treatment Guidelines; Looking to Future Research for Non-Responders to IFN-Free Treatment
December 14, 2016
- Taltz Issue Exposes Forex-Sensitive Nature of Drug Pricing System
November 15, 2016
- Are Biosimilars on Verge of Breakthrough in Japan? Initiatives Underway to Prepare for Full-Scale Entry of Major Biosimilars
October 25, 2016
- Policymakers Face Balancing Act over Opdivo Re-Pricing
October 17, 2016
- Can Wholesalers Bear Distribution Costs amid 90% Discount on Generics?
October 11, 2016
- Can Mid-sized Makers Break Away from Long-Listed Product Model?
August 19, 2016
- MHLW’s Feat to Link Drug Review and Reimbursement Policies Put to Test with “Expensive Drugs”
June 28, 2016
- 7 Drugs Picked for Cost-Effective Assessments, but Now How Will They Be Re-Priced Exactly?
May 27, 2016
- Data Corroborate Harshness of Z2 Rule, Only Handful to Escape 2nd Consecutive Application
March 31, 2016
- Global Pharmas Casting Colder Eyes on Japan Market; PhRMA, EFPIA to Up Lobbying Efforts with Govt, Ruling Parties
March 11, 2016
- Companies Can “Veto” Humanitarian Trials for Legitimate Reasons; Cooperation Is Essential, but Access Scheme Shouldn’t Stymie Main Development
February 23, 2016
- It’s Time to Squarely Discuss Proposed Penalty through Drug Price Cuts
February 3, 2016
ページ
Takeda Pharmaceutical completed the £46 billion acquisition of Shire on January 8, vaulting itself into the top 10 league of…
To many people, Japan has always been one of the world’s most advanced economies and a market of rich opportunities with one of the top healthcare systems worldwide.Add a rapidly changing demographic, a declining workforce, and the constant challenges of…
While generic drugs post solid growth in volume-based shares in Japan, their makers are pondering ways to retool their business…